- The trend backdrop is active with a 6-week active streak.
- Price is above the Trend Line, keeping the weekly tape constructive.
- Price is above Fair Value, showing premium demand versus the model.
- Activity pressure is positive on the latest completed week.
RPGLIFE
NSI
Week ended 07 Aug 2026
Weekly Investor Report
RPG Life Sciences Limited · Healthcare · Drug Manufacturers - Specialty & Generic
Latest close
2,661 INR
-3.9%
latest week
Weekly setup
Mixed setup
The weekly trend is active. Price is 20.2% above the Trend Line and sits at 68.8% of its 52-week range. The latest completed week returned -3.9%, after a -6.8% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth ranks weakly; valuation is expensive relative to peers. The latest news-sentiment score is 58/100. Near-term considerations: volume confirmation is below normal.
Setup score
55
out of 100
Latest Close
2,661 INR
7 Aug 2026
1W Return
-3.9%
latest completed week
4W Return
-6.8%
short-term follow-through
12W Return
16.1%
quarterly tape
Trend Breadth
40.4%
21 of 52 weeks active
Volume Ratio
0.6x
vs 13-week average
- 2 reversal markers appear in the recent smart-money tape.
- Recent volatility is running well above the one-year baseline.
- Latest weekly return ranks in the weaker part of its sector group.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
-3.9%
Latest completed week; four-week move -6.8%.
Indicator stack
43/81
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
News sentiment
58/100
27 relevant articles in the latest sentiment read.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is active. Price is 20.2% above the Trend Line and sits at 68.8% of its 52-week range. The latest completed week returned -3.9%, after a -6.8% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 0.6x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
7 Aug
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.8112-week average 0.58
12-week confirmation
Trend active6/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure12/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership12/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.81Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers22 reversal markers
No recent accumulation markers. 2 reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is -6.8% over four weeks, 16.1% over 12 weeks, and 13.7% over one year. The current trend has remained active for 6 consecutive weeks.
Performance by holding period
Active trend streak6 weeks
Active weeks in one year21
Trend breadth40.4%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure1.44Latest activity-pressure read.
Pressure change61.4%Four-week change in activity pressure.
Leadership18.46Latest relative-leadership reading.
RS change-40.5%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality is middle-of-the-pack; growth ranks weakly; valuation is expensive relative to peers.
Factor week 09 Aug 2026
Financial statements through 31 Mar 2026
Field coverage 94%
Model confidence 88%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength39/100Blend of value, momentum, and quality. Underlying universe rank 62; rank 1 is best.
Value18/100Relative valuation strength. Underlying universe rank 83; rank 1 is best.
Quality70/100Profitability and accounting quality. Underlying universe rank 31; rank 1 is best.
Momentum78/100Medium-term price momentum. Underlying universe rank 23; rank 1 is best.
Growth16/100Revenue and earnings growth. Underlying universe rank 85; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Value-quality framework36/100Value and quality alignment from the Sharemaestro SVQF framework.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- 22.5x Price divided by trailing earnings.
- Price / sales
- 6.6x Market value relative to trailing revenue.
- EV / EBITDA
- 16.3x Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- -0.2% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- 65.0% Gross profit retained from each unit of revenue.
- Operating margin
- 16.7% Operating profit retained from revenue.
- Free-cash-flow margin
- -1.3% Free cash flow generated from revenue.
- Return on invested capital
- 17.7% Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- 8.4% Latest one-year revenue growth.
- EPS growth
- -37.1% Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- -121.2% Latest one-year free-cash-flow growth.
- Piotroski F-score
- 3/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- 0.9% Cash dividends relative to market value.
- Buyback yield
- 0.0% Net share repurchases relative to market value.
- Shareholder yield
- 0.9% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- -0.5x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Insider activity-
No recent insider transactions are stored for this company.
News sentiment58/100
Weighted news tone is neutral across 27 relevant articles.
10 positive · 17 neutral · 0 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-13.7%Distance below the 52-week high.
13-week volatility6.5%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
13 Feb
13 Mar
10 Apr
8 May
5 Jun
3 Jul
7 Aug
Weeks higher13 of 2613 weeks finished lower.
Best week+19.4%Week of 10 Jul.
Worst week-6.9%Week of 15 May.
Latest week-3.9%Week of 7 Aug.
Shape of recent returns
Strong gains5
Modest gains8
Flat weeks0
Modest losses11
Sharp losses2
Recent vol6.5%13-week weekly-return volatility.
Base vol4.7%52-week weekly-return volatility.
Up/down split25/27Count of positive and negative weeks in the 52-week window.
Average skew3.7% / -2.7%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorIN Healthcare
4-week rank87 / 100
Group average1.2%
Trend breadth83.0%
Trend83.0%active weekly trend signals
MD85.0%positive activity pressure
RS73.0%positive relative leadership
Four-week leaders
IndustryIN Drug Manufacturers - Specialty & Generic
4-week rank75 / 92
Group average1.0%
Trend breadth76.1%
Trend76.1%active weekly trend signals
MD80.4%positive activity pressure
RS65.2%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape57/100
Trend, activity pressure, participation, and risk combine to a 57/100 tape read.
Indicator analysis72/100Latest 12-week confirmation: trend 6/12, activity pressure 12/12, relative leadership 12/12.
Activity pressure 0.81; 2 reversal markers Factors50/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 51; Small Cap Core rank 73 SVQF36/100Value and quality alignment from the Sharemaestro SVQF framework.
Composite rank 1014.0 of 1576 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Sentiment58/100Weighted news tone is neutral across 27 relevant articles.
RPG Life Sciences VP Samir Rane retires on July 31, 2026 Insiders50/100No recent insider transaction evidence is stored.
Earnings50/100No stored earnings event is currently attached to this ticker.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 7 Aug 2026 | 2,661 INR | -3.9% | 2,214 INR | 1,997 INR | 1.44 | 18.46 | 55.6K | On |
| 31 Jul 2026 | 2,768 INR | -5.7% | 2,204 INR | 1,987 INR | 1.66 | 24.48 | 112.1K | On |
| 24 Jul 2026 | 2,937 INR | 2.7% | 2,188 INR | 1,976 INR | 1.54 | 36.01 | 209.1K | On |
| 17 Jul 2026 | 2,860 INR | 0.1% | 2,169 INR | 1,964 INR | 1.22 | 29.99 | 277.2K | On |
| 10 Jul 2026 | 2,857 INR | 19.4% | 2,152 INR | 1,952 INR | 0.89 | 31.02 | 381.6K | On |
| 3 Jul 2026 | 2,392 INR | 6.1% | 2,134 INR | 1,940 INR | 0.59 | 9.83 | 6.0K | On |
| 26 Jun 2026 | 2,254 INR | -0.0% | 2,128 INR | 1,930 INR | 0.52 | 4.41 | 0 | Off |
| 19 Jun 2026 | 2,255 INR | 2.7% | 2,128 INR | 1,921 INR | 0.56 | 4.64 | 3.1K | Off |
| 12 Jun 2026 | 2,195 INR | 2.5% | 2,128 INR | 1,912 INR | 0.64 | 3.53 | 20.7K | Off |
| 5 Jun 2026 | 2,140 INR | -3.8% | 2,132 INR | 1,904 INR | 0.74 | 2.05 | 11.9K | Off |
| 29 May 2026 | 2,225 INR | -3.0% | 2,140 INR | 1,896 INR | 0.98 | 5.40 | 38.7K | Off |
| 22 May 2026 | 2,294 INR | 0.1% | 2,146 INR | 1,886 INR | 1.19 | 8.06 | 32.6K | Off |
| 15 May 2026 | 2,292 INR | -6.9% | 2,148 INR | 1,876 INR | 1.06 | 8.56 | 42.7K | Off |
| 8 May 2026 | 2,463 INR | 7.3% | 2,148 INR | 1,867 INR | 0.89 | 14.35 | 349.4K | Off |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.